Last reviewed · How we verify
AFFITOPE AD01 adjuvanted — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
AFFITOPE AD01 adjuvanted (AFFITOPE AD01 adjuvanted) — Affiris AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AFFITOPE AD01 adjuvanted TARGET | AFFITOPE AD01 adjuvanted | Affiris AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AFFITOPE AD01 adjuvanted CI watch — RSS
- AFFITOPE AD01 adjuvanted CI watch — Atom
- AFFITOPE AD01 adjuvanted CI watch — JSON
- AFFITOPE AD01 adjuvanted alone — RSS
Cite this brief
Drug Landscape (2026). AFFITOPE AD01 adjuvanted — Competitive Intelligence Brief. https://druglandscape.com/ci/affitope-ad01-adjuvanted. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing